How does PRCT's PS Ratio compare to its peers?

PRCT is expensive based on its Price-To-Sales Ratio (25.1x) compared to the peer average (9.5x).

How does PRCT's PS Ratio compare vs other companies in the US Medical Equipment Industry?

PRCT is expensive based on its Price-To-Sales Ratio (25.1x) compared to the US Medical Equipment industry average (3.1x).

What is PRCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRCT is expensive based on its Price-To-Sales Ratio (25.1x) compared to the estimated Fair Price-To-Sales Ratio (5.5x).

What is the Fair Price of PRCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate PRCT's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

PROCEPT BioRobotics (Nasdaq:PRCT) - Stock Price, News & Analysis

PRCT Stock Overview

A surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. More details

PRCT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 24.61% per year

Risk Analysis

Volatile share price over the past 3 months compared to the US market

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

PROCEPT BioRobotics Corporation Competitors

Inspire Medical Systems

NYSE:INSP

US$5.3b

Axonics

NasdaqGS:AXNX

US$3.6b

TransMedics Group

NasdaqGM:TMDX

US$2.8b

Shockwave Medical

NasdaqGS:SWAV

US$12.6b

Price History & Performance

Summary of all time highs, changes and price drops for PROCEPT BioRobotics
Historical stock prices
Current Share Price	US$92.70
52 Week High	US$103.81
52 Week Low	US$33.45
Beta	1
11 Month Change	35.92%
3 Month Change	15.49%
1 Year Change	167.15%
33 Year Change	150.00%
5 Year Change	n/a
Change since IPO	121.03%

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Oct 31

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Oct 31

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Sep 12

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Aug 27

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Aug 25

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

Aug 04

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10

Shareholder Returns

	PRCT	US Medical Equipment	US Market
7D	0.5%	-0.4%	-1.0%
1Y	167.1%	20.3%	30.3%

Return vs Industry: PRCT exceeded the US Medical Equipment industry which returned 20.9% over the past year.

Return vs Market: PRCT exceeded the US Market which returned 30.4% over the past year.

Price Volatility

Is PRCT's price volatile compared to industry and market?
PRCT volatility
PRCT Average Weekly Movement	13.4%
Medical Equipment Industry Average Movement	8.2%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: PRCT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PRCT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2007	626	Reza Zadno	www.procept-biorobotics.com

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH.

PROCEPT BioRobotics Corporation Fundamentals Summary

How do PROCEPT BioRobotics's earnings and revenue compare to its market cap?
PRCT fundamental statistics
Market cap	US$5.06b
Earnings (TTM)	-US$100.06m
Revenue (TTM)	US$199.84m

25.1x

P/S Ratio

-50.1x

P/E Ratio

Is PRCT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRCT income statement (TTM)
Revenue	US$199.84m
Cost of Revenue	US$85.16m
Gross Profit	US$114.68m
Other Expenses	US$214.74m
Earnings	-US$100.06m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.85
Gross Margin	57.39%
Net Profit Margin	-50.07%
Debt/Equity Ratio	22.2%

How did PRCT perform over the long term?

See historical performance and comparison

PRCT Stock Overview

Rewards

Risk Analysis

PROCEPT BioRobotics Corporation Competitors

NYSE:INSP

US$5.3b

NasdaqGS:AXNX

US$3.6b

NasdaqGM:TMDX

US$2.8b

NasdaqGS:SWAV

US$12.6b

Price History & Performance

Recent News & Updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $174.999916 million.

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation has filed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation to Report Q3, 2024 Results on Oct 28, 2024

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $174.999916 million.

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation has filed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation to Report Q3, 2024 Results on Oct 28, 2024

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

PROCEPT BioRobotics Corporation Revises Revenue Guidance for Full Year 2024

PROCEPT BioRobotics Corporation to Report Q2, 2024 Results on Aug 01, 2024

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$65.00

Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024

First quarter 2024 earnings released: US$0.51 loss per share (vs US$0.63 loss in 1Q 2023)

PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 04, 2024

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation to Report Q1, 2024 Results on May 01, 2024

President recently sold US$263k worth of stock

Executive VP & CFO exercised options to buy US$2.6m worth of stock.

President recently sold US$428k worth of stock

Independent Director notifies of intention to sell stock

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Price target increased by 11% to US$56.67

PROCEPT BioRobotics Corporation Provides Revenue Guidance for the Full Year 2024

Full year 2023 earnings: EPS misses analyst expectations

Executive VP & CFO notifies of intention to sell stock

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Price target increased by 7.3% to US$51.17

Price target increased by 12% to US$50.33

Executive VP & CFO exercised options and sold US$702k worth of stock

PROCEPT BioRobotics Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 7.6% to US$47.17

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Independent Chairman of the Board recently sold US$3.1m worth of stock

Executive VP & CFO notifies of intention to sell stock

Price target decreased by 7.9% to US$40.67

Independent Director recently sold US$805k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Revenue Guidance for the Full Year 2023

PROCEPT BioRobotics Corporation to Report Q3, 2023 Results on Nov 01, 2023

Procept Biorobotics Corporation Receives U.S. Fda Investigational Device Exemption to Investigate Aquablation Therapy for Prostate Cancer

PROCEPT Biorobotics Corporation Announces First Commercial Aquablation Therapy Procedures in Japan

Price target decreased by 7.6% to US$47.29

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $149.999972 million.

Insider exercised options and sold US$280k worth of stock

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2023

PROCEPT BioRobotics Corporation to Report Q2, 2023 Results on Jul 27, 2023

Executive VP & CFO recently sold US$795k worth of stock

Insider exercised options to buy US$366k worth of stock.

First quarter 2023 earnings: EPS misses analyst expectations

President recently sold US$170k worth of stock